RxDoctor Payments Data

Mohamed Khalil, MD

Neurology · Webster, TXNPI 1124391198

Payments from drug & device makers

$60,803in general payments, 2019–2025

Across 850 payments — averaging $71.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • H. Lundbeck A S$35K
  • Novartis$11K
  • AbbVie$2K
  • UCB, Inc.$1K
  • SK Life Science, Inc.$889
  • Lundbeck LLC$675
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$550%
  • Travel & lodging$190%
  • Food & beverage$16,83999%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
H. Lundbeck A S14$34,632
Novartis88$10,834
AbbVie(2 entities)113$1,875
UCB, Inc.59$1,444
SK Life Science, Inc.38$889
Lundbeck LLC38$675
Takeda Pharmaceuticals U.S.A., Inc.29$674
Grifols USA, LLC38$660
Pfizer32$633
Jazz Pharmaceuticals Inc.23$563
AstraZeneca(2 entities)29$542
Eisai Inc.24$511
Argenx US, Inc.19$502
Neurocrine Biosciences, Inc.17$407
Sanofi16$383
Teva Pharmaceuticals USA, Inc.18$354
Biogen17$330
Biohaven Pharmaceutical Holding Company Ltd.12$268
Genentech USA, Inc.16$260
Acadia Pharmaceuticals Inc16$249
Kerecis Limited1$222
Biohaven Pharmaceuticals, Inc.9$194
ANI Pharmaceuticals, Inc.10$190
W. L. Gore & Associates, Inc.1$182
Mallinckrodt Hospital Products Inc.9$172
CSL Behring7$169
TG Therapeutics, Inc.9$167
Lilly USA, LLC11$165
Kyowa Kirin, Inc.3$163
Amgen8$158
Aquestive Therapeutics, Inc.8$150
Hospira, Inc.6$131
Assertio Therapeutics, Inc.7$123
Abbott6$106
Johnson & Johnson3$100
Boston Scientific4$96
Vertical Pharmaceuticals, LLC6$93
Supernus Pharmaceuticals, Inc.3$92
Octapharma USA, Inc.2$85
Catalyst Pharmaceuticals, Inc.4$85
Corium, LLC3$81
Springworks Therapeutics, Inc.4$80
Arbor Pharmaceuticals, Inc.6$79
Avion Pharmaceuticals5$77
Sumitomo Pharma America, Inc.4$71
MDD US Operations, LLC4$70
Acorda Therapeutics, Inc3$55
Aucta Pharmaceuticals, Inc.8$54
EMD Serono, Inc.3$54
Azurity Pharmaceuticals, Inc.3$50
Amneal Pharmaceuticals LLC3$45
Livanova USA, Inc.2$45
Ipsen Biopharmaceuticals, Inc2$43
Upsher-smith Laboratories LLC2$42
Otsuka America Pharmaceutical, Inc.2$42
GE HealthCare1$40
Promius Pharma LLC2$38
Banner Life Sciences, LLC2$33
Amarin Pharma, Inc.2$31
Tanabe Pharma America, Inc.2$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,803 in reported general payments places this provider in the 80th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$499,575
Medicare patients
383
Services billed
27,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov50365$5,732,806
Gamunex-CImmune Globul G/Gly/Iga Avg 46361$2,845,740
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50119$1,798,272
GammakedImmune Globul G/Gly/Iga Avg 4668$1,620,436
PanzygaImmun Glob G(Igg)-Ifas/Glycine46$918,991
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5059$679,712
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5015$266,258
BotoxOnabotulinumtoxina69$126,632
AubagioTeriflunomide11$101,607
UbrelvyUbrogepant24$31,743
QuliptaAtogepant12$23,285
Aimovig AutoinjectorErenumab-Aooe18$16,957
RytaryCarbidopa/Levodopa26$11,655
Memantine Hcl540$11,090
Rivastigmine50$7,803

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Panzyga$633$6,651,797411 claims
Grifols USA, LLCGamunex-C$660$2,845,740361 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$674$1,798,272119 claims
CSL BehringPrivigen$169$679,71259 claims
AbbVieBotox, Ubrelvy, Qulipta$1,875$181,660105 claims
SanofiAubagio$383$101,60711 claims
Amneal Pharmaceuticals LLCRytary$45$11,65526 claims
Upsher-smith Laboratories LLCTopiramate$42$64446 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,246 neurology providers in Texas.

Other neurology in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →